Isatuximab SC-OBDS

DEVICE2 trials

Sponsors

Sanofi, Massachusetts General Hospital

Conditions

Plasma Cell Myeloma RefractoryRelapsed Refractory Multiple MyelomaRelapsed Refractory Multiple Myeloma (RRMM)

Phase 2

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

RecruitingNCT06356571

SanofiPlasma Cell Myeloma Refractory

Start: 2025-03-17End: 2027-07-15Target: 64Updated: 2026-02-23

ELISA in Relapsed/Refractory MM

RecruitingNCT06832865

Massachusetts General HospitalRelapsed Refractory Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM)

Start: 2025-08-14End: 2028-12-01Target: 30Updated: 2026-03-12

Related Papers

Trial in Progress: Phase 2 Study of Subcutaneous Isatuximab, Administered By an on-Body Delivery System, in Combination with Weekly Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (SubQSA)

Blood2024-11-051 citations